(PharmaNewsWire.Com, January 18, 2017 ) Idiopathic short stature (ISS) refers to children with shorten growth of body where the reason behind the physical condition is unknown. The children with height less than 2 standard deviations (SDs) are categorized in this clinical condition. The group of idiopathic short children includes children with delay of growth and puberty, hereditary short stature, children with subtle cartilage and bone dysplasias. There is no precise medical cause for ISS, whereas some reasons include genetic structure and other orthopedic related complications.
The disease often diagnosed by X-rays of the left wrist or hand along with complete blood count, growth hormone stimulation test, insulin growth factor-1 test and other blood related tests. Though there is ongoing debate about treatment of ISS based on growth hormones but based on the physical and blood test, generally hormonal therapy is recommended by health care professionals In 2003, United States Food and Drug Administration (FDA) approved human growth hormone treatment for children with idiopathic short stature (height below 2.25 SD). According to survey conducted by European Society of Endocrinologist, 94% physicians prefer growth hormone treatment for ISS.
Children with idiopathic short stature can be found in all parts of the world. According to The Endocrine Society based in United States, It is estimated that approximately 60 – 80% of all children across the globe with short stature fit in the category of ISS and therefore total number of people living with ISS will increase accordingly. The above fact stands for demand of various treatment options for ISS globally. The heavy investment in research and development, suitable reimbursement conditions and growing number of patients living with ISS may drive the growth of the market. On the other hand limited awareness and lack of specific treatment may hinder the growth of the overall market.
Currently many established players in pharmaceuticals market which are either catering or on the way to develop drugs for idiopathic short stature. Out of these companies, JCR Pharmaceuticals Co., Braasch Biotech LLC, Bolder Biotechnology, Inc., Myungmoon pharmaceutical Co. Ltd, Eli Lilly, Pfizer are leading contributors.
This research report analyzes this market on the basis of its market segments, major geographies, and current market trends. Geographies analyzed under this research report include North America Asia Pacific Europe Rest of the World This report provides comprehensive analysis of Market growth drivers Factors limiting market growth Current market trends Market structure Market projections for upcoming years This report is a complete study of current trends in the market, industry growth drivers, and restraints. It provides market projections for the coming years. It includes analysis of recent developments in technology, Porter’s five force model analysis and detailed profiles of top industry players. The report also includes a review of micro and macro factors essential for the existing market players and new entrants along with detailed value chain analysis.
Reasons for Buying this Report This report provides pin-point analysis for changing competitive dynamics It provides a forward looking perspective on different factors driving or restraining market growth It provides a six-year forecast assessed on the basis of how the market is predicted to grow It helps in understanding the key product segments and their future
We are pleased to offer you this exciting, new, and entirely free professional resource. Visit our Free Biotechnology & Pharmaceuticals resource center today to browse our selection of 600+ complimentary Biotechnology & Pharmaceuticals magazines, white papers, webinars, podcasts, and more. Get popular titles including:
